Envudeucitinib, a Potent, Next-Generation, Allosteric Inhibitor of TYK2: A Narrative Review

By afschroeder • April 5, 2026

Armstrong AW, Krueger JG, Strober BE, Stein Gold LF, Desai SR, Muscianisi E, Klyachkin Y, Ucpinar S, Tilley MK, Blauvelt A. Envudeucitinib, a Potent, Next-Generation, Allosteric Inhibitor of TYK2: A Narrative Review. Dermatol Ther (Heidelb). 2026 Apr 4. doi: 10.1007/s13555-026-01727-9. Epub ahead of print. PMID: 41934538.

Tags: autoimmune disease, Dermatology, envudeucitinib, ESK-001, Next-generation oral, psoriasis, Publications, TYK2

Incubating Artificial Intelligence (AI) Initiatives and Careers in Dermatology

Wongvibulsin S, Primiero CA, Adamson AS, Barata C, Betz-Stablein B, Celebi ME, Dawant B, Guitera P, Kelly KM, Kittler H, Kose K, Landman B, Lehman[...]

Neutrophil Transcriptomic Changes in Severe Sterile Vasoplegic Syndrome Resemble a Distinct Molecular Subtype of Septic Shock

Siletz AE, Kelly-Scumpia KM, Scumpia PO, Street K, Ragkousis V, Shirazi R, Sanaiha Y, Do TH, Shemin R, Kwon M, Crager S, Benharash P, Cryer[...]

Systemic Pharmacological Treatments for Chronic Plaque Psoriasis

Armstrong AW, Nong Y, Merola JF. Systemic Pharmacological Treatments for Chronic Plaque Psoriasis. JAMA Dermatol. 2026 Mar 25. doi: 10.1001/jamadermatol.2026.0200. Epub ahead of print. PMID:[...]